KA/EN
Register
Medicines reference
Search
Search
Product

Speybact

Favourites

Ampicillin + Sulbactam · Spey Medical Pvt. Ltd.

1 form: powder. No registration in force in Georgia.

Forms and doses0 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Dose Frequency Georgia
1.5 g, Powder · Cat Cat 10–30 mg/kg
Dose is the combined ampicillin+sulbactam mixture. The published range is formulary guidance; direct feline combination PK/outcome evidence and an exact-product feline study were not located. Use only with culture/indication justification and close monitoring. Prepare ex tempore and verify current exact-pack limits.
 · every 6-8 hours		 every 6-8 hours Georgia Suspended
Suspended or cancelled
Human (Ministry of Health, RAMA)
№ რ-035044
Verified on: 22 Oct 2026
1.5 g, Powder · Dog Dog 10–30 mg/kg
Dose is the combined ampicillin+sulbactam mixture. Direct critically ill/septic-peritonitis dog PK shows variable target attainment; culture/MIC, source control, renal function and clinical response must guide selection. Prepare ex tempore; verify current exact-pack post-reconstitution limits.
 · every 6-8 hours		 every 6-8 hours Georgia Suspended
Suspended or cancelled
Human (Ministry of Health, RAMA)
№ რ-035044
Verified on: 22 Oct 2026
Details: pack, label wording, sources, registration

Speybact 1.5 g, Powder

powder for solution for injection, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Hospital IV treatment of a serious susceptible bacterial infection; culture-directed where possible, with empirical use limited to strong suspicion and prompt reassessment/de-escalation
Not rateable
No numerical score assigned
vetman assessment

Speybact

1.5 g, powder for solution for injection, human medicine
Assessed clinical scopeDog · Hospital IV treatment of a serious susceptible bacterial infection; culture-directed where possible, with empirical use limited to strong suspicion and prompt reassessment/de-escalation · Intravenous
Care settingVeterinary hospital use with sampling/culture, source control, aseptic reconstitution, frequent IV administration, renal/hepatic review and clinical/microbiological reassessment
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Suspended · № რ-035044 · Verified on 22 Oct 2026 Off-label use
Not rateable

The ampicillin-sulbactam combination has direct canine PK and a veterinary formulary regimen, but this exact Speybact registration is suspended for absent GMP evidence. Current lawful supply and batch quality are unresolved, so the exact presentation cannot receive a responsible clinical score.

The active combination and veterinary IV use are clinically interpretable, but the exact product remains unscoreable while its Georgian registration is suspended for absent GMP evidence and current batch quality is unresolved. Comparator quality cannot validate Speybact.

Important safety and use flags

  • This is a human product. All dog/cat use is off-label and must follow veterinary antimicrobial governance.
  • The Georgian registration is suspended because the register reports no GMP certificate. Retail availability does not mean active authorisation or verified current batch quality.
  • Reserve for a serious proven or strongly suspected susceptible bacterial infection. Obtain samples before treatment when feasible, review culture/MIC and de-escalate to the narrowest effective agent.
  • Antibiotic therapy does not replace drainage, debridement, foreign-body removal, surgery or other source control, and this product is not routine prophylaxis or minor-infection therapy.
  • The 10-30 mg/kg dose is the total 2:1 ampicillin+sulbactam mixture. Do not interpret it as 10-30 mg/kg of ampicillin plus additional sulbactam.
  • Direct critically ill dog PK shows variable target attainment. Do not assume Enterobacterales or resistant-organism coverage without susceptibility and patient-context review.
  • Direct feline combination PK, outcome and exact-product evidence were not located. Cat efficacy and safety confidence are lower and extrapolation must be explicit.
  • Prepare ex tempore, maintain asepsis and compatibility, and verify the current exact pack for post-reconstitution limits. The human IM label does not establish a companion-animal IM regimen.
  • Avoid in serious beta-lactam hypersensitivity/cross-reactivity or prior ampicillin-sulbactam cholestatic injury. Adjust for renal impairment and consider sodium load, seizures at excessive exposure, GI/hepatic injury and cytopenias.
  • Never reconstitute or mix with an aminoglycoside because ampicillin can inactivate it in vitro. Monitor clinical response, culture/MIC, renal/hepatic status, CBC, GI tolerance and bacterial/fungal superinfection.
Assessment sources
  1. Speybact manufacturer instruction2017
  2. Speybact GE register audit2026
  3. Ampicillin-sulbactam comparator label2026
  4. MSD veterinary ampicillin-sulbactam dose2026
  5. AAFP/AAHA stewardship2022
  6. Canine septic-peritonitis PK2022
  7. Critically ill dog PK2025
  8. Dog combination PK1990
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Cat Hospital IV treatment of a serious susceptible bacterial infection; culture-directed where possible, with empirical use limited to strong suspicion and prompt reassessment/de-escalation
Not rateable
No numerical score assigned
vetman assessment

Speybact

1.5 g, powder for solution for injection, human medicine
Assessed clinical scopeCat · Hospital IV treatment of a serious susceptible bacterial infection; culture-directed where possible, with empirical use limited to strong suspicion and prompt reassessment/de-escalation · Intravenous
Care settingVeterinary hospital use with sampling/culture, source control, aseptic reconstitution, frequent IV administration, renal/hepatic review and clinical/microbiological reassessment
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Suspended · № რ-035044 · Verified on 22 Oct 2026 Off-label use
Not rateable

A veterinary formulary regimen exists, but direct feline combination evidence is sparse and this exact Speybact registration is suspended for absent GMP evidence. Current lawful supply and batch quality are unresolved, so the exact presentation cannot receive a responsible clinical score.

The active combination and veterinary IV use are clinically interpretable, but the exact product remains unscoreable while its Georgian registration is suspended for absent GMP evidence and current batch quality is unresolved. Comparator quality cannot validate Speybact.

Important safety and use flags

  • This is a human product. All dog/cat use is off-label and must follow veterinary antimicrobial governance.
  • The Georgian registration is suspended because the register reports no GMP certificate. Retail availability does not mean active authorisation or verified current batch quality.
  • Reserve for a serious proven or strongly suspected susceptible bacterial infection. Obtain samples before treatment when feasible, review culture/MIC and de-escalate to the narrowest effective agent.
  • Antibiotic therapy does not replace drainage, debridement, foreign-body removal, surgery or other source control, and this product is not routine prophylaxis or minor-infection therapy.
  • The 10-30 mg/kg dose is the total 2:1 ampicillin+sulbactam mixture. Do not interpret it as 10-30 mg/kg of ampicillin plus additional sulbactam.
  • Direct critically ill dog PK shows variable target attainment. Do not assume Enterobacterales or resistant-organism coverage without susceptibility and patient-context review.
  • Direct feline combination PK, outcome and exact-product evidence were not located. Cat efficacy and safety confidence are lower and extrapolation must be explicit.
  • Prepare ex tempore, maintain asepsis and compatibility, and verify the current exact pack for post-reconstitution limits. The human IM label does not establish a companion-animal IM regimen.
  • Avoid in serious beta-lactam hypersensitivity/cross-reactivity or prior ampicillin-sulbactam cholestatic injury. Adjust for renal impairment and consider sodium load, seizures at excessive exposure, GI/hepatic injury and cytopenias.
  • Never reconstitute or mix with an aminoglycoside because ampicillin can inactivate it in vitro. Monitor clinical response, culture/MIC, renal/hepatic status, CBC, GI tolerance and bacterial/fungal superinfection.
Assessment sources
  1. Speybact manufacturer instruction2017
  2. Speybact GE register audit2026
  3. Ampicillin-sulbactam comparator label2026
  4. MSD veterinary ampicillin-sulbactam dose2026
  5. AAFP/AAHA stewardship2022
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Ampicillin1000 mg Sulbactam500 mg
Formulation Type
Powder
Administration route
Intravenous, Intramuscular
Registration
Georgia Suspended
Suspended or cancelled
Human (Ministry of Health, RAMA)
№ რ-035044
Verified on: 22 Oct 2026
 EU Not confirmed
Verified on: 22 Oct 2026
 UK Not confirmed
Verified on: 22 Oct 2026
 US Not confirmed
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Exact vial: ampicillin 1 g plus sulbactam 0.5 g. Veterinary guidance gives the combined mixture 10-30 mg/kg IV q6-8h for dogs and cats; do not read it as an ampicillin-only dose. Prepare ex tempore and aseptically according to the public manufacturer instruction; verify the current pack for post-reconstitution limits. Keep aminoglycosides physically separate, sample/culture when feasible and reassess/de-escalate promptly. No companion-animal IM regimen is established.
DoseSpeciesWeightRouteFrequencySource
10–30 mg/kg
Dose is the combined ampicillin+sulbactam mixture. The published range is formulary guidance; direct feline combination PK/outcome evidence and an exact-product feline study were not located. Use only with culture/indication justification and close monitoring. Prepare ex tempore and verify current exact-pack limits.
 Cat Any weight Intravenous every 6-8 hours
MSD veterinary ampicillin-sulbactam dose
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
Penicillins Use in Animals
MSD/Merck Veterinary Manual, 2026
10–30 mg/kg
Dose is the combined ampicillin+sulbactam mixture. Direct critically ill/septic-peritonitis dog PK shows variable target attainment; culture/MIC, source control, renal function and clinical response must guide selection. Prepare ex tempore; verify current exact-pack post-reconstitution limits.
 Dog Any weight Intravenous every 6-8 hours
MSD veterinary ampicillin-sulbactam dose
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
Penicillins Use in Animals
MSD/Merck Veterinary Manual, 2026
Active substance doses, with sources
Active substance Ampicillin
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
10–20 mg/kg Dog Bacterial Infection By mouth 2 times daily
VMD SPC 2018
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Ampicare 250 mg Hard Capsules - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2018
10–40 mg/kg
off-label
 Dog Bacterial Infection Intravenous every 6-12 hours
MSD veterinary ampicillin-sulbactam dose
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
Penicillins Use in Animals
MSD/Merck Veterinary Manual, 2026
6.6–20 mg/kg
off-label
 Cat Bacterial Infection Intravenous every 8-12 hours
MSD veterinary ampicillin-sulbactam dose
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
Penicillins Use in Animals
MSD/Merck Veterinary Manual, 2026

Sulbactam: No dose supported by a publicly verifiable source yet

Known Contraindications

  • Critical Ampicillin
    Not to be administered to animals known to be sensitive to penicillin. in individuals with a history of serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to ampicillin, sulbactam or to other beta-lactam antibacterial drugs (e.g., penicillins and cephalosporins)
    Sources: VMD SPC · VMD · FDA
  • Critical Ampicillin
    contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with ampicillin and sulbactam for injection.
    Sources: FDA

Known Drug Interactions

  • Major warning Ampicillin + Dihydrostreptomycin
    Ampicillin and Sulbactam for Injection and aminoglycosides should not be reconstituted together due to the in vitro inactivation of aminoglycosides by the ampicillin component.
    Recommendation: Reconstitute and administer separately at different sites. Do not run them concurrently through the same line.
    Sources: FDA
  • Major warning Ampicillin + Doxycycline
    It is not recommended to administer bactericidal and bacteriostatic antibiotics concomitantly.
    Recommendation: If both are required, support the choice with culture and susceptibility results. Otherwise, choose one mechanism.
    Sources: VMD SPC · VMD
  • Major warning Ampicillin + Oxytetracycline
    Do not give oxytetracycline at the same time as bactericidal antimicrobials such as penicillins or cephalosporins because their antibacterial effects may be antagonistic.
    Recommendation: Do not administer concurrently.

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (59 more) Hide additional products

Same therapeutic group 59

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗